GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

DelveInsight's data-driven approach not only illuminated the path forward but also positioned the client as a frontrunner in biomarker-driven NSCLC therapies. This case study showcases how ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, ...

There are many roles to play in overcoming P.E.I.’s housing crisis. The Construction Association of P.E.I. and provincial government are helping people from a variety of backgrounds take up their part ...